Methotrexaat ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-004472-35-NL (EUCTR) | 02/03/2015 | 01/12/2014 | TREAT EARLY ARTHRALGIA TO REVERSE OR LIMIT IMPENDING EXACERBATION TO RHEUMATOID ARTHRITIS | TREAT EARLY ARTHRALGIA TO REVERSE OR LIMIT IMPENDING EXACERBATION TO RHEUMATOID ARTHRITIS | Arthralgia of hands or feet of patients that are suspect to progress to reumatoid arthritis according to the treating rheumatologist and because of subclinical inflammation on MRI of hands and feet (Clinical Suspect Artralgia CSA);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Methotrexaat Product Name: Methotrexaat Product Code: L04AX03 INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Trade Name: Methylprednisolone Product Name: Methylprednisolone Product Code: H02AB04 INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE ACETATE | Leiden University medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 230 | Phase 2 | Netherlands |